Health product recall

Blood Group Reagent Anti-Lea (Murine Monoclonal)Bioclone

Last updated

Summary

Product
Blood Group Reagent Anti-Lea (Murine Monoclonal)Bioclone
Issue
Medical devices - Performance issue
What to do

Contact the manufacturer if you require additional information. 

Audience
Healthcare

Affected products

Affected products

Lot or serial number

Model or catalogue number

Blood Group Reagent Anti-Lea (Murine Monoclonal)Bioclone

LAB167A
LAB169A
LAB168A
LAB170A

715280

Issue

During an internal investigation, Ortho identified that the Anti-Lea (Anti-Le1) lot LAB170A was demonstrating weak to no reactivity with Lea positive cells. The results of the investigation demonstrated that lot LAB170A was more than two dilutions lower than the control lot, thereby these lots were failing internal testing. This issue of weak/no reactivity of Anti-Lea (Anti-Le1) antisera may be detectable in both quality control (QC) and patient samples based on weakened strength of reactivity.

Recall start date: June 29, 2022

Additional information

Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Medical devices - Haematology
Companies

Ortho-Clinical Diagnostics Inc.

1001 Us Hwy 202, Raritan, New Jersey, United States, 08869

Published by
Health Canada
Audience
Healthcare
Recall class
Type II
Identification number
RA-64355

Get notified

Receive notifications for new and updated recalls and alerts by category.

Subscribe